Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds

• Status: Terminated
• Trial end date: 2020-08-30
• Target enrollment: 0
• Participant gender: All

Summary

To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Government of Punjab, Specialized Healthcare and Medical Education Department
• Collaborators: Forman Christian College; Forman Christian College, Pakistan; Harvard School of Public Health; Harvard School of Public Health (HSPH); Mayo Hospital Lahore; Pakistan Kidney and Liver Institute; Services Institute of Medical Sciences, Pakistan
• Treatments: Chloroquine; Hydroxychloroquine

Criteria

Inclusion Criteria:

1. Nasopharyngeal RT-PCR positive SARS-CoV-2 patient

2. Age 20-50 years

3. BMI 18-28 kg/m2

4. Informed consent

Exclusion Criteria:

1. Symptoms: Cough, fever, shortness of breath

2. O2 saturation by pulse-oximeter below 94%

3. Co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes

4. Arrhythmias and/or history of arrythmia

5. Psoriasis and/or history of psoriasis

6. Neuropathy or myopathy and/or history of these

7. Hypoglycemia and/or history of hypoglycemia

8. Pre-existing hepatic disease

9. Pre-existing renal disease

10. Use of antacids within 1 week

11. Use of antibiotics within 1 week

12. Pregnancy

13. RT-PCR performed >3 days prior to enrollment